Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 2
1986 8
1987 3
1988 1
1989 6
1990 4
1991 13
1992 10
1993 4
1994 2
1995 9
1996 6
1997 7
1998 4
1999 9
2000 14
2001 14
2002 9
2003 10
2004 10
2005 6
2006 11
2007 13
2008 8
2009 5
2010 8
2011 6
2012 4
2013 6
2014 5
2015 4
2016 4
2017 4
2018 10
2019 6
2020 7
2021 7
2022 7
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

260 results

Results by year

Filters applied: . Clear all
Page 1
Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
Mathew R, Di Santo P, Jung RG, Marbach JA, Hutson J, Simard T, Ramirez FD, Harnett DT, Merdad A, Almufleh A, Weng W, Abdel-Razek O, Fernando SM, Kyeremanteng K, Bernick J, Wells GA, Chan V, Froeschl M, Labinaz M, Le May MR, Russo JJ, Hibbert B. Mathew R, et al. N Engl J Med. 2021 Aug 5;385(6):516-525. doi: 10.1056/NEJMoa2026845. N Engl J Med. 2021. PMID: 34347952 Clinical Trial.
The treatment groups did not differ significantly with respect to the primary outcome; a primary outcome event occurred in 47 participants (49%) in the milrinone group and in 52 participants (54%) in the dobutamine group (relative risk, 0.90; 95% confidence interval [CI], …
The treatment groups did not differ significantly with respect to the primary outcome; a primary outcome event occurred in 47 participants ( …
Milrinone Versus Sildenafil in Treatment of Neonatal Persistent Pulmonary Hypertension: A Randomized Control Trial.
Imam SS, El-Farrash RA, Taha AS, Saleh GA. Imam SS, et al. J Cardiovasc Pharmacol. 2022 Nov 1;80(5):746-752. doi: 10.1097/FJC.0000000000001332. J Cardiovasc Pharmacol. 2022. PMID: 35881893 Clinical Trial.
The 24-hour and 48-hour post-treatment OSI values were much lower in the milrinone group than those in the sildenafil group ( P < 0.05). ...Milrinone is superior to sildenafil in improving oxygenation without lowering blood pressure parameters....
The 24-hour and 48-hour post-treatment OSI values were much lower in the milrinone group than those in the sildenafil group ( P & …
Levosimendan or Milrinone for Ventricular Septal Defect Repair With Pulmonary Arterial Hypertension.
Nag P, Chowdhury SR, Behera SK, Das M, Narayan P. Nag P, et al. J Cardiothorac Vasc Anesth. 2023 Jun;37(6):972-979. doi: 10.1053/j.jvca.2023.01.032. Epub 2023 Feb 6. J Cardiothorac Vasc Anesth. 2023. PMID: 36906394 Clinical Trial.
In the present study, the authors sought to compare the role of levosimendan and milrinone in the prevention of low-cardiac-output syndrome in the early postoperative period. ...CONCLUSIONS: In patients undergoing surgical repair for VSD with PAH, levosimendan does not con …
In the present study, the authors sought to compare the role of levosimendan and milrinone in the prevention of low-cardiac-output sy …
Levosimendan Versus Milrinone and Release of Myocardial Biomarkers After Pediatric Cardiac Surgery: Post Hoc Analysis of Clinical Trial Data.
Thorlacius EM, Vistnes M, Ojala T, Keski-Nisula J, Molin M, Romlin BS, Synnergren M, Ricksten SE, Wåhlander H, Castellheim A. Thorlacius EM, et al. Pediatr Crit Care Med. 2021 Jul 1;22(7):e402-e409. doi: 10.1097/PCC.0000000000002712. Pediatr Crit Care Med. 2021. PMID: 33739957 Clinical Trial.
We hypothesized that levosimendan could attenuate the degree of myocardial injury when compared with milrinone. DESIGN: A post hoc, nonprespecified exploratory secondary analysis of the Milrinone versus Levosimendan-1 trial (ClinicalTrials.gov Identifier: NCT0223239 …
We hypothesized that levosimendan could attenuate the degree of myocardial injury when compared with milrinone. DESIGN: A post hoc, n …
Comparison of the efficacy of inhaled versus infused milrinone in the management of persistent pulmonary hypertension of the newborn in resource-limited settings: A randomized clinical trial.
Choobdar FA, Shahhosseini P, Vahedi Z, Khosravi N, Khalesi N, Ghassemzadeh M. Choobdar FA, et al. Pediatr Pulmonol. 2023 Jul;58(7):2132-2139. doi: 10.1002/ppul.26451. Epub 2023 May 3. Pediatr Pulmonol. 2023. PMID: 37133219 Clinical Trial.
Overall, 83.9% of the participants achieved full recovery, 75% of whom were in the infusion group and 93.3% in the inhalation group (p = 0.186). CONCLUSION: Milrinone inhalation can have similar effects to milrinone infusion as an adjunct treatment in the management …
Overall, 83.9% of the participants achieved full recovery, 75% of whom were in the infusion group and 93.3% in the inhalation group (p = 0.1 …
Inotropic and lusitropic effects of levosimendan and milrinone assessed by strain echocardiography-A randomised trial.
Fredholm M, Jörgensen K, Houltz E, Ricksten SE. Fredholm M, et al. Acta Anaesthesiol Scand. 2018 Oct;62(9):1246-1254. doi: 10.1111/aas.13170. Epub 2018 Jun 21. Acta Anaesthesiol Scand. 2018. PMID: 29926912 Clinical Trial.
BACKGROUND: We compared the direct inotropic and lusitropic effects of two inodilators, milrinone and levosimendan in patients after aortic valve replacement for aortic stenosis. ...CONCLUSIONS: At clinically relevant infusion rates and a certain increase in LV performance …
BACKGROUND: We compared the direct inotropic and lusitropic effects of two inodilators, milrinone and levosimendan in patients after …
Implications of Myocardial Infarction on Management and Outcome in Cardiogenic Shock.
Jung RG, Di Santo P, Mathew R, Abdel-Razek O, Parlow S, Simard T, Marbach JA, Gillmore T, Mao B, Bernick J, Theriault-Lauzier P, Fu A, Lau L, Motazedian P, Russo JJ, Labinaz M, Hibbert B. Jung RG, et al. J Am Heart Assoc. 2021 Nov 2;10(21):e021570. doi: 10.1161/JAHA.121.021570. Epub 2021 Oct 29. J Am Heart Assoc. 2021. PMID: 34713704 Free PMC article. Clinical Trial.
Background The randomized DOREMI (Dobutamine Compared to Milrinone) clinical trial evaluated the efficacy and safety of milrinone and dobutamine in patients with cardiogenic shock. ...Methods and Results Patients in cardiogenic shock (n=192) were randomized 1:1 to d …
Background The randomized DOREMI (Dobutamine Compared to Milrinone) clinical trial evaluated the efficacy and safety of milrinone
Arrhythmic Events and Mortality in Patients With Cardiogenic Shock on Inotropic Support: Results of the DOREMI Randomized Trial.
Jung RG, Di Santo P, Mathew R, Simard T, Parlow S, Weng W, Abdel-Razek O, Malhotra N, Cheung M, Hutson JH, Marbach JA, Motazedian P, Thibert MJ, Fernando SM, Nery PB, Nair GM, Russo JJ, Hibbert B, Ramirez FD. Jung RG, et al. Can J Cardiol. 2023 Apr;39(4):394-402. doi: 10.1016/j.cjca.2022.09.013. Epub 2022 Sep 20. Can J Cardiol. 2023. PMID: 36150583 Clinical Trial.
Existing data on the incidence and significance of arrhythmic events in patients with CS on inotropic support is at high risk of bias. METHODS: The Dobutamine Compared to Milrinone (DOREMI) trial randomized patients to receive dobutamine or milrinone in a double-bli …
Existing data on the incidence and significance of arrhythmic events in patients with CS on inotropic support is at high risk of bias. METHO …
Acute effects of intravenous milrinone in heart failure.
Rettig GF, Schieffer HJ. Rettig GF, et al. Eur Heart J. 1989 Aug;10 Suppl C:39-43. doi: 10.1093/eurheartj/10.suppl_c.39. Eur Heart J. 1989. PMID: 2680496 Review.
Milrinone exerts positive inotropic and dose-dependent vasodilatory effects that promote haemodynamic improvement after intravenous administration to patients with heart failure. ...Improved performance of the right ventricle is due primarily to reduced right ventricular a
Milrinone exerts positive inotropic and dose-dependent vasodilatory effects that promote haemodynamic improvement after intravenous a
Safety and clinical utility of long-term intravenous milrinone in advanced heart failure.
Mehra MR, Ventura HO, Kapoor C, Stapleton DD, Zimmerman D, Smart FW. Mehra MR, et al. Am J Cardiol. 1997 Jul 1;80(1):61-4. doi: 10.1016/s0002-9149(97)00284-1. Am J Cardiol. 1997. PMID: 9205021 Clinical Trial.
Few data are available on the long-term safety or clinical utility of the inodilator agent milrinone. We designed a prospective, nonrandomized, observational trial in a cohort of 71 patients who had demonstrated dependence on inotropic therapy, had been clinically stable o …
Few data are available on the long-term safety or clinical utility of the inodilator agent milrinone. We designed a prospective, nonr …
260 results